Stem Cell Transplant and Cellular Therapies on Multiple Myeloma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 206
Special Issue Editor
Interests: multiple myeloma; pembrolizumab; lenalidomide; dexamethasone; multiple myeloma therapy; relapsed multiple myeloma; QoL; quality of life; haematopoietic stem cell transplantation; biochemistry and molecular biology
Special Issue Information
Dear Colleagues,
Stem cell transplant remains a cornerstone in multiple myeloma treatment. Cellular therapies are emerging as promising treatments in the relapsed and refractory setting and may even challenge frontline treatment options. The use of a patient's own stem cells or immune cells is key to obtaining long-lasting remission in different parts of the multiple myeloma treatment journey.
Recent trials have confirmed the role of autologous stem cell transplantation to deepen the response in the course of first-line treatment, even after optimized induction treatment combinations. The role of allogeneic stem cell options is controversial; however, it is still a preferred option for ultra-high-risk patients, including those with plasma cell leukemia.
The use of genetically modified T or NK cells from the patient or from healthy donors has also shown dramatic activity in the relapse and refractory setting. Autologous CAR-T cells directed against the B cell maturation antigen (BCMA) have been marketed after the outstanding results of recent phase 2 trials. Furthermore, phase 3 results support the use of CAR-T cells in earlier lines. CAR-T therapy is likely to challenge consolidation and maintenance strategies or even autologous stem cell transplantation in the near future. Allogeneic CAR-T cells are the ideal method to achieving the “off-the-shelf” availability of cellular immunotherapy. The clinical results of allogeneic CAR-T cells do not match those of autologous products yet, but technology continues to evolve rapidly.
In this Special Issue, original reviews and articles that focus on the current use of stem cell transplant and cellular therapies on multiple myeloma are welcome.
Dr. Albert Oriol
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- stem cell transplant
- cellular therapy
- CAR T cell
- multiple myeloma
- T or NK cells
